



LKT Laboratories, Inc.

MK-2206 Dihydrochloride

Phone: 888-558-5227
651-644-8424
Fax: 888-558-7329
Email: getinfo@lktlabs.com
Web: lktlabs.com

Product Information


Product ID M400220
CAS No. 1032350-13-2
Chemical Name MK-2206 Dihydrochloride

Synonym MK-2206 hydrochloride

Formula $C_{25}H_{21}N_5O \cdot 2HCl$
Formula Wt. 480.39
Melting Point
Purity $\geq 99\%$
Solubility

Store Temp $-20^{\circ}C$
Ship Temp Ambient

Description MK-2206 is an allosteric inhibitor of Akt that prevents translocation of Akt to membranes. MK-2206 exhibits anticancer chemotherapeutic activity in a variety of in vitro cancer models; this compound induces G1-phase cell cycle arrest in hepatocellular carcinoma cells, inhibits cell proliferation in non-small cell lung cancer cells, and inhibits proliferation in medullary thyroid cancer cells. In animal models of nasopharyngeal cancer, MK-2206 inhibits tumor growth. TEST!!!!!!



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
M400220	5 mg	\$45.00
M400220	25 mg	\$125.00
M400220	100 mg	\$350.00

References Zhao YY, Tian Y, Zhang J, et al. Effects of an oral allosteric AKT inhibitor (MK-2206) on human nasopharyngeal cancer in vitro and in vivo. *Drug Des Devel Ther.* 2014 Oct 10;8:1827-37. PMID: 25336925.

Burke JF, Schlosser L, Harrison AD, et al. MK-2206 Causes Growth Suppression and Reduces Neuroendocrine Tumor Marker Production in Medullary Thyroid Cancer Through Akt Inhibition. *Ann Surg Oncol.* 2013 Nov;20(12):3862-8. PMID: 23900743.

Jiao P, Zhou YS, Yang JX, et al. MK-2206 induces cell cycle arrest and apoptosis in HepG2 cells and sensitizes TRAIL-mediated cell death. *Mol Cell Biochem.* 2013 Jun 25. [Epub ahead of print] PMID: 23797319.

Jin R, Nakada M, Teng L, et al. Combination therapy using Notch and Akt inhibitors is effective for suppressing invasion but not proliferation in glioma cells. *Neurosci Lett.* 2013 Feb 8;534:316-21. PMID: 23262078.

Quayle SN, Lee JY, Cheung LW, et al. Somatic mutations of PIK3R1 promote gliomagenesis. *PLoS One.* 2012;7(11):e49466. PMID: 23166678.

Iida M, Brand TM, Campbell DA, et al. Targeting AKT with the allosteric AKT inhibitor MK-2206 in non-small cell lung cancer cells with acquired resistance to cetuximab. *Cancer Biol Ther.* 2013 Jun;14(6):481-91. PMID: 23760490.

Davies BR, Greenwood H, Dudley P, et al. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. *Mol Cancer Ther.* 2012 Apr;11(4):873-87. PMID: 22294718.

Cheng Y, Zhang Y, Zhang L, et al. MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. *Mol Cancer Ther.* 2012 Jan;11(1):154-64. PMID: 22057014.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.